Double-blind Placebo Controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Dosing of GLPG0634 in Healthy Subjects

Trial Profile

Double-blind Placebo Controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Dosing of GLPG0634 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2015

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Nov 2012 Results will be presented at the 2012 Annual Meeting of the American College of Rheumatology (ACR) according to a Galapagos media release.
    • 25 Oct 2011 Actual end date (1 Oct 2011) added as reported by ClinicalTrials.gov.
    • 25 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top